Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe.
Mocroft A, Geressu A, Beguelin C, Llibre JM, Lazarus JV, Tomazic J, Smidt J, Parczewski M, Brännström J, Sedlacek D, Degen O, van der Valk M, Paduta D, Flamholc L, Schmid P, Orkin C, Nielsen LN, Hoffmann C, Beniowski M, Oprea C, Begovac J, Peters L. Mocroft A, et al. Among authors: llibre jm. AIDS. 2023 Jan 1;37(1):91-103. doi: 10.1097/QAD.0000000000003406. Epub 2022 Oct 18. AIDS. 2023. PMID: 36476454
Platelet count kinetics following interruption of antiretroviral treatment.
Zetterberg E, Neuhaus J, Baker JV, Somboonwit C, Llibre JM, Palfreeman A, Chini M, Lundgren JD; INSIGHT SMART Study Group. Zetterberg E, et al. Among authors: llibre jm. AIDS. 2013 Jan 2;27(1):59-68. doi: 10.1097/QAD.0b013e32835a104d. AIDS. 2013. PMID: 23018440 Free PMC article. Clinical Trial.
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Puertas MC, Massanella M, Llibre JM, Ballestero M, Buzon MJ, Ouchi D, Esteve A, Boix J, Manzardo C, Miró JM, Gatell JM, Clotet B, Blanco J, Martinez-Picado J; MaraviBoost Collaborative Group. Puertas MC, et al. Among authors: llibre jm. AIDS. 2014 Jan 28;28(3):325-34. doi: 10.1097/QAD.0000000000000066. AIDS. 2014. PMID: 24185044 Clinical Trial.
Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression.
Llibre JM, Cozzi-Lepri A, La Rosa JA, Pedersen C, Ristola M, Losso M, Mocroft A, Mitsura VM, Ormaasen V, Maltez F, Beniowski M, Paredes R; Eurosida in Eurocoord. Llibre JM, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19810. doi: 10.7448/IAS.17.4.19810. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397554 Free PMC article.
Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study.
Llibre JM, Cozzi-Lepri A, Pedersen C, Ristola M, Losso M, Mocroft A, Mitsura V, Falconer K, Maltez F, Beniowski M, Vullo V, Hassoun G, Kuzovatova E, Szlavik J, Kuznetsova A, Stellbrink HJ, Duvivier C, Edwards S, Laut K, Paredes R; EuroSIDA Study. Llibre JM, et al. Medicine (Baltimore). 2016 Oct;95(40):e5020. doi: 10.1097/MD.0000000000005020. Medicine (Baltimore). 2016. PMID: 27749561 Free PMC article.
267 results